BioVersys (private company)
BioVersys is a Switzerland-based pharmaceutical company developing BV100, a potential breakthrough hospital antibiotic to treat serious infections caused by carbapenem resistant Acinetobacter baumannii (CRAB) in indications of ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP) and bloodstream infections (BSI).
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Investments 60.96m
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Belgium
Netherlands
Austria
Germany
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden
France
Ireland
Italy
Portugal
Spain
United Kingdom